| Identification | Back Directory | [Name]
Benzamide, 3,4-dimethoxy-N-[5-[[4-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]sulfonyl]-1-naphthalenyl]- | [CAS]
2531244-56-9 | [Synonyms]
BJJF078
Benzamide, 3,4-dimethoxy-N-[5-[[4-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]sulfonyl]-1-naphthalenyl]- | [Molecular Formula]
C27H29N3O6S | [MOL File]
2531244-56-9.mol | [Molecular Weight]
523.6 |
| Chemical Properties | Back Directory | [density ]
1.36±0.1 g/cm3(Predicted) | [solubility ]
DMSO: Soluble: =10 mg/ml
Ethanol: Sparingly Soluble: 1-10 mg/ml | [form ]
Solid | [pka]
12.45±0.43(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BJJF078 is an aminopiperidine derivative. BJJF078 is a potent inhibitor of recombinant human and mouse Transglutaminase enzyme (TG2) activity, IC50 values of 41 and 54 nM, respectively. BJJF078 also inhibits the close related enzyme TG1, with an IC50 of 0.16 μM. BJJF078 can be used for Multiple sclerosis (MS) research[1]. | [References]
[1] Chrobok NL, et al. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. PLoS One. 2018 Apr 24;13(4):e0196433. DOI:10.1371/journal.pone.0196433 |
|
|